Alvee Discussion started by Alvee 6 years ago
In a study of 112 MS patients self-medicating with cannabis in the US and UK, Consroe et al[5] reported that 70% of more respondents reported improvement in the following symptoms:

 

Spasticity at sleep onset

Pain in muscles

Spasticity when awaking at night

Pain in legs at night

Tremor (arms/head)

Depression

Anxiety

Spasticity when waking in morning

Spasticity when walking

Tingling in face/arms/head/trunk

Numbness of chest/stomach

Pain in face

Weight loss

Weakness in legs

 

The authors considered these reports åstrongly suggested cannabinoids may significantly relieve symptoms of MS, particularly spasticity and pain", and provided sufficient grounds for a properly controlled clinical trial to test such claims objectively and conclusively.

 

A German study of 170 self-medicating cannabis users found 11% of respondents reported using the drug successfully in managing MS symptoms, the second most common use behind depression and concluded "this study demonstrates a successful use of cannabis products for the treatment of a multitude of various illnesses and symptoms. This use was usually accompanied only by slight and in general acceptable side effects." Mechoulam[7] reviews illegal use of cannabis by MS patients. In a UK survey of 318 MS patients, 8% reported using cannabis to relieve symptoms.

 

In a survey of 780 MS patients in Canada, Page et al[9] found "Forty-three percent had tried cannabis at some point in their lives, 16% for medicinal purposes. Symptoms reported to be ameliorated included anxiety/depression, spasticity and chronic pain" and concluded, "Subjective improvements in symptom experience were reported by the majority of people with MS who currently use cannabis." A survey of 131 patients with amyotrophic lateral sclerosis[10], of which only 13 used cannabis, found "cannabis may be moderately effective at reducing symptoms of appetite loss, depression, pain, spasticity, and drooling". Simmons et al[11] studied responses to an internet survey by 2529 respondents, finding cannabis commonly reported as beneficial. Clarke et al[12] surveyed 220 MS patients in Canada, finding "Medical cannabis use was associated with male gender, tobacco use, and recreational cannabis use. The symptoms reported by medical cannabis users to be most effectively relieved were stress, sleep, mood, stiffness/spasm, and pain." Ware et al[13] reported results of a survey of medicinal cannabis use in the UK, noting "Medicinal cannabis use was reported by patients with chronic pain (25%), multiple sclerosis and depression (22% each), arthritis (21%) and neuropathy (19%). Medicinal cannabis use was associated with younger age, male gender and previous recreational use (p < 0.001)."

 

In the Netherlands, cannabis has been available on prescription from pharmacies since September 2003, Erkens et al[14] followed up 200 patients prescribed the drug with a questionnaire survey, finding "Cannabis was mainly used for chronic pain and muscle cramp/stiffness.The indication of medicinal cannabis use was in accordance with the labeled indications. However, more than 80% of the patients still obtained cannabis for medicinal purpose from the illegal circuit. Because of the higher prices in pharmacies, ongoing debate on the unproven effectiveness of the drug and the hesitation by physicians to prescribe cannabis."

http://www.idmu.co.uk/canmsreview.htm

American States University

 CSi_Updates_Outline2.jpgDrug Valuation Image3


 

 Recent GBXI News:

June 22, 2023, GBX International Group, Inc., (OTC: GBXI)
Breaking Cancer Barriers; Investments in Low-Cost, Harvard Award-Winning, Effective Cancer Killing Drugs Now; GBXI Proceeds to Raise $1 Million to Fast-Track its' Success, Cancer Drug Valuations, Access for Patients, Full Company Audit, and Accelerate the Trading of the CSi-Spinout Shares

 

May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets


April 21, 2023, GBX International Group, Inc., (OTC: GBXI)

HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans 



Harvard GHC Award RCD 2018

 

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

 

Click here to review the Report:

Frontiers Capture
1mmStrong July 8 Court UPDATE Brochure Image

Sac Court Capture

Case No. 2:17-CV-02271-KJM-JDP



Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB
 



Observational Studies

PART

Notifications

Activity Stream

I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever... Show more

Raymond C. Dabney Raymond C. Dabney Great questions as usual Francis, some a bit over the line comments and questions, but I get it.

"We Own everything we speak about Owning,...
Show more
2 days ago
loader
loader
Attachment
Raymond C. Dabney Raymond C. Dabney Everything has it's Priority. Not being sick anymore was Priority Number 1.

Now that I'm past that NASTY Sickness phase we can...
Show more
2 days ago
loader
loader
Attachment

Hi Raymond,

Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:

On November 8, 2023; Capizate, Inc. (a 3rd party entity)...
Show more

Raymond C. Dabney You're welcome and Thank you Francis! It's been a Battle, that's for sure! Playing catch up with everyone responding to the Legacy Drug Ownership... Show more 2 months ago
loader
loader
Attachment
Raymond C. Dabney Thanks for reading our updates Guys! That is correct we are ALL waiting patiently for the same stock exchange approval process.

Not sure how many...
Show more
2 months ago
loader
loader
Attachment
Alvin Kline Who would be nice to see some trading going on won't be long I'm going to be in granite City I hope it don't take that long 7 days ago
loader
loader
Attachment
Alvin Kline Well for waiting for the government to get anything done we're in big trouble because they don't even know who the hell the president is yet 4 days ago
loader
loader
Attachment
Alvin Kline Steak eating congressman they can't get off their ass cuz they're too damn fat to do anything 4 days ago
loader
loader
Attachment

Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"

HARVARD Award Winning 
CANCER Killing Success





1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

Frontiers_1.JPG


2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

 Frontiers_2.JPG


*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

WhatsApp_Image_2022-05-21_at_9.37.37_AM_3.jpg
Skin Cancer 

WhatsApp_Image_2022-05-21_at_9.37.38_AM.jpeg
Karposis Sarcoma

WhatsApp_Image_2022-05-21_at_9.37.38_AM_1.jpeg

CSi Final GIFT Share Issuance Nov 27 2022



Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

 LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

ASU/CSi-EDP-ECO-System
At it's FINEST !!! 

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.



2023 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2023

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296

Class A Common Stock
Authorized:
100,000,000
Issued:
0

Class B Common Stock
Authorized:
1,500,000,000
Issued:
0

Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000



Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE




*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!

 

Events

Sorry, we currently have no events.
View All Events